PATENT CLAIM ANALYSIS

Application Number: 16213550
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "265100"]

Abstract:
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.

Claim (Index 26):
The method of  claim 1 , wherein the myeloproliferative neoplasm is selected from polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis, chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), systemic mast cell disease (SMCD), chronic neutrophilic leukemia (CNL), and chronic eosinophilic leukemia.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 98.0
- Lexical Diversity: 1.45652
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15373923', '14811038', '15815255', '14155212', '15166380']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7996323505210008
- 35 USC 102 Novelty (BERT): 0.5708225588323306
- Combined Prediction Score: 0.7767513713521338
- Mean Citation Score: 428.94012
- Max Citation Score: 460.80817
- Similarity Product: 361.0065958584976

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test